

Title (en)

USE OF CORE 2 GLCNAC TRANSFERASE INHIBITORS IN TREATING INFLAMMATION

Title (de)

VERWENDUNG VON INHIBITOREN DER ZENTRALEN GLCNAC-TRANSFERASE BEI DER BEHANDLUNG VON ENTZÜNDUNGEN

Title (fr)

UTILISATION D'INHIBITEURS DE 2 GLCNAC TRANSFERASE CENTRALE DANS LE TRAITEMENT D'INFLAMMATION

Publication

EP 1131334 A1 20010912 (EN)

Application

EP 99959043 A 19991120

Priority

- US 9927465 W 19991120
- US 10941698 P 19981121
- US 11367998 P 19981221

Abstract (en)

[origin: WO0031109A1] This invention provides compounds and methods for treating inflammation. The compounds modulate the core 2 oligosaccharide-mediated binding of inflammatory cells, such as neutrophils, to endothelial cells and other myeloid cells. Significantly, the of the invention methods block inflammation without affecting lymphocyte trafficking. In some embodiments, the compounds inhibit the activity of a core 2 GlcNAc transferase that is involved in synthesizing the core 2 oligosaccharides.

IPC 1-7

C07H 21/04; **C07K 16/00**; **C12N 15/63**; **C12N 15/85**; **A61K 48/00**

IPC 8 full level

A61K 31/711 (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 1/00** (2006.01); **A61P 9/10** (2006.01); **A61P 11/04** (2006.01); **A61P 29/00** (2006.01); **A61P 31/04** (2006.01); **A61P 43/00** (2006.01); **C12N 9/10** (2006.01)

CPC (source: EP)

A61P 1/00 (2017.12); **A61P 9/10** (2017.12); **A61P 11/04** (2017.12); **A61P 29/00** (2017.12); **A61P 31/04** (2017.12); **A61P 43/00** (2017.12); **C12N 9/1048** (2013.01); **C07K 2319/30** (2013.01)

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0031109 A1 20000602; AU 1629700 A 20000613; CA 2347940 A1 20000602; EP 1131334 A1 20010912; EP 1131334 A4 20030521; JP 2002530425 A 20020917

DOCDB simple family (application)

US 9927465 W 19991120; AU 1629700 A 19991120; CA 2347940 A 19991120; EP 99959043 A 19991120; JP 2000583936 A 19991120